Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

BIO IP News Weekly for April 17, 2009

The IP News Weekly took a break the past couple of weeks, but this week marks my returned coverage. Visit http://www.bio.org/ip/documents/IPNewsWeeklyApril172009.pdf to view the weekly newsletter in PDF form. To subscribe to the newsletter via email, email me at mnoriega@bio.org.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

IP Counsels Committee Conference in Phoenix Discusses Patent Reform

At the latest IP Counsels Committee Conference this past March, Q. Todd Dickinson, Executive Director of the American Intellectual Property Law Association (AIPLA), and E. Anthony Figg of Rothwell, Figg, Ernst & Manbeck, P.C., spoke to BIO’s member companies, universities, and law firm members about patent reform legislation. Patent Docs‘ Donald Zuhn wrote about Dickinson and Figg on Patent Reform yesterday: In the three weeks since the panel session took place, Senate Judiciary Committee Chairman Patrick Leahy Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Federal Trade Commission holds “Evolving IP Marketplace” hearing on Friday, April 17, 2009

The Federal Trade Commission (FTC) is hosting another meeting in a series entitled “The Evolving IP Marketplace.”

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

The Blunders of In Re Kubin

A recent U.S. Federal Circuit of Appeals decision (In Re Kubin) distorts the definition of a patentable invention, threatening the future of biotechnology innovation in the United States. Read our summary.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO IP News Weekly for March 20, 2009

BIO’s weekly newsletter of stories compiled from a variety of public news sources, previously only available to BIO members, is now publicly available: See our temporary version here to check out the news we’re following for March 20, 2009.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: